Skip to Navigation | Skip To Content

Strontium and Arthritis

The mineral strontium (present in the Bone Health product) has been shown to improve both osteoporosis and arthritis, and even decrease bone pain in cancer patients. This newest study showed that taking the strontium also decreased back pain associated with spine arthritis while actually preventing progression of the arthritis. Below are the study's findings.

Effects of Strontium Ranelate on Spinal Osteoarthritis Progression

O Bruyere1, D Delferriere1, C Roux2, J D Wark3, T Spector4, J-P Devogelaer5, K Brixen6, S Adami7, J Fechtenbaum2, S Kolta2, J-Y Reginster1

Objective: The aim of this study was to determine whether a 3-year treatment with strontium ranelate could delay the progression of spinal osteoarthritis (OA).

Methods: This study was a post-hoc analysis of pooled data from the Spinal Osteoporosis Therapeutic Intervention (SOTI) and TReatment Of Peripheral OSteoporosis (TROPOS) trials performed on 1105 women with osteoporosis and concomitant radiological spinal OA at baseline, and for whom lumbar x-rays were available at baseline and over the 3-year treatment period. The presence and severity of osteophytes, disc space narrowing and sclerosis in the lumbar intervertebral spaces was graded according to a validated method, and an overall OA score was calculated for each intervertebral space. Back pain (measured on a five-point Likert scale only in SOTI) and health-related quality of life (SF-36 questionnaire) were assessed at baseline and after 3 years. Patients who suffered an incident or progressive vertebral fracture during the study were excluded from the analysis.

Results: The proportion of patients with worsening overall spinal OA score was reduced by 42% in the strontium ranelate group, compared with placebo (RR, 0.58; 95% CI, 0.42 to 0.79; p = 0.0005). Significantly more patients in the strontium ranelate group experienced an improvement in back pain after 3 years, compared with placebo (p = 0.03), while no significant difference was observed in terms of health-related quality of life between these patient groups.

Conclusions: The results of this post-hoc analysis suggest that strontium ranelate could reduce the progression of the radiographic features of spinal OA and back pain in women with osteoporosis and prevalent spinal OA.

Reference:

Published Online First: 26 October 2007. doi:10.1136/ard.2007.075572 Annals of the Rheumatic Diseases 2008;67:335-339



This Week's Special Offers

The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. The information on this website is not intended to diagnose, treat, cure or prevent any disease.

Sign In